ADC targeting both PSMA and STEAP1 with a topoisomerase payload showed a 15-month PFS signal in heavily pretreated prostate ...
Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens. As he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results